These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 13469412)

  • 1. Investigation into the existence of functionally deficient Vi antibody. II. Passive mouse protection tests with sera prepared by immunization with different typhoid vaccines.
    SPAUN J; BENTZON MW
    Acta Pathol Microbiol Scand; 1957; 41(4):342-52. PubMed ID: 13469412
    [No Abstract]   [Full Text] [Related]  

  • 2. Investigation into the existence of functionally deficient Vi antibody. I. An analysis of the protective effects of S. typhi O and Vi antibodies on intraperitoneal typhoid infection of mice.
    SPAUN J; BENTZON MW
    Acta Pathol Microbiol Scand; 1957; 41(4):327-41. PubMed ID: 13469411
    [No Abstract]   [Full Text] [Related]  

  • 3. Active and passive mouse protection tests used in the assay of typhoid vaccines.
    TOLNAI G; BARSY G
    Acta Microbiol Acad Sci Hung; 1957; 4(3):227-36. PubMed ID: 13487253
    [No Abstract]   [Full Text] [Related]  

  • 4. A study of the molecular types of immunoglobulin. II. Mouse protection study of Vi antibody against typhoid infection.
    Kawata Y
    Acta Sch Med Univ Kioto; 1970 Mar; 40(3):284-90. PubMed ID: 4194346
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
    Tacket CO; Pasetti MF; Sztein MB; Livio S; Levine MM
    J Infect Dis; 2004 Aug; 190(3):565-70. PubMed ID: 15243933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Demonstration of the effect of typhoid vaccines and sera through blood culture in a mouse test].
    LIPP R
    Z Immun exp ther; 1957 Aug; 114(2-3):235-43. PubMed ID: 13478071
    [No Abstract]   [Full Text] [Related]  

  • 7. T.A.B. studies; merthiolate as preservative of VI-antigen in T.A.B. vaccine. II. Passive mouse protection.
    GERICHTER CB; SILBERSTEIN W
    Acta Med Orient; 1956 Jan; 15(1):10-7. PubMed ID: 13313046
    [No Abstract]   [Full Text] [Related]  

  • 8. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings.
    Zhou WZ; Koo HW; Wang XY; Zhang J; Park JK; Zhu F; Deen J; Acosta CJ; Chen Y; Wang H; Galindo CM; Ochiai L; Park T; von Seidlein L; Xu ZY; Clemens JD
    Pediatr Infect Dis J; 2007 Nov; 26(11):1001-5. PubMed ID: 17984806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Typhoid vaccine; Vi antigen and Vi antibody.
    SPAUN J
    Acta Pathol Microbiol Scand Suppl (1926); 1957; 123():1-79. PubMed ID: 13487335
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of epidemiology in the introduction of vi polysaccharide typhoid fever vaccines in Asia.
    Acosta CJ; Galindo CM; Ochiai RL; Danovaro-Holliday MC; Page AL; Thiem VD; Park JK; Park E; Koo H; Wang XY; Abu-Elyazeed R; Ali M; Albert MJ; Ivanoff B; Pang T; Xu ZY; Clemens JD
    J Health Popul Nutr; 2004 Sep; 22(3):240-5. PubMed ID: 15609776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Household demand for typhoid fever vaccines in Hue, Vietnam.
    Do GC; Whittington D; Le TK; Utomo N; Nguyen TH; Poulos C; Dang TD; Kim D; Nyamete A; Acosta C
    Health Policy Plan; 2006 May; 21(3):241-55. PubMed ID: 16581824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Incomplete antibodies in typhoid fever. II. Vi agglutination].
    POTUZNIK V; HAVLIK J
    Cesk Epidemiol Mikrobiol Imunol; 1957 Sep; 6(5):322-4. PubMed ID: 13479888
    [No Abstract]   [Full Text] [Related]  

  • 13. [Production, reactions and immunization capacity of typhoid-dysentery-tetanus polyvaccines].
    RAUSS K; KETYI I; RETHY L; JOO I
    Z Immun exp ther; 1958 Sep; 116(3):287-307. PubMed ID: 13604530
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immunizing power of adsorbed anti typhoid vaccines prepared with bacterial suspensions treated with ultrasonics or cryolysates].
    ROBERT L
    Arch Maragliano Patol Clin; 1957 Apr; 13(2):229-34. PubMed ID: 13445395
    [No Abstract]   [Full Text] [Related]  

  • 15. Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?
    Pulickal AS; Pollard AJ
    Expert Rev Vaccines; 2007 Jun; 6(3):293-5. PubMed ID: 17542742
    [No Abstract]   [Full Text] [Related]  

  • 16. Detection of O-acetylated Vi polysaccharide of Salmonella enterica subspecies typhi by enzyme immunoassay.
    Rijpkema S; Durrani Z; Lemercinier X; Jones C
    Biologicals; 2004 Mar; 32(1):11-6. PubMed ID: 15026021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Behavior of anti-Vi antibodies during typhoid fever].
    GOSCICKI J; KUKULSKA T; STEMPIEN R
    Przegl Epidemiol; 1956; 10(4):325-32. PubMed ID: 13420219
    [No Abstract]   [Full Text] [Related]  

  • 18. [First typhoid fever vaccination attempts in France (1911-1913)].
    RENDU R
    Prog Med (Paris); 1954 Dec; 82(24):520-2. PubMed ID: 14357435
    [No Abstract]   [Full Text] [Related]  

  • 19. Experimental investigations on two types of T.A.B. vaccine prepared from microbial extracts adsorbed on a mineral support.
    ILIESCU M; MITRICA N; MESROBEANU L
    Rum Med Rev; 1957; 1(2):24-5. PubMed ID: 13495298
    [No Abstract]   [Full Text] [Related]  

  • 20. Studies on the antibody in the blood sera of immune individuals with TAB vaccine.
    NAGAKI D; ANZAI H; IWASAKI K; TAKAMATSU K; UCHIYAMA T
    Kitasato Arch Exp Med; 1952 Oct; 25(2):69-82. PubMed ID: 13097701
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.